Founded
31 Dec 2000
VCID: 112319
Profile
Corporate information
Official name
Chroma Therapeutics
Registration country
Official name
Chroma Therapeutics
Registration country
Investment activity status
Active investor
Company type
Focused on harnessing the power of chromatin biology and novel drug accumulation approaches to discover and develop a new generation of targeted canceFunding
Funding rounds
(3 Apr 2006)
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Gilde Investment Management | Netherlands | ||
|
|
Phase4 Ventures Ltd | United Kingdom | ||
|
Wellcome Trust | United Kingdom |
(31 Dec 2001)
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Abingworth Bioventures III LP | Venture capital fund | United Kingdom |
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Essex Woodlands Health Ventures Inc | United States | ||
|
ETV Capital SA | United Kingdom | ||
|
Hercules Technology Growth Capital Inc | Specialised finance company providing debt and equity growth capital to technology-related companies at all stages of development. | United States | |
|
University of Cambridge | United Kingdom |
Cap Table
Current and past shareholders
| Investor | Contacts | Round | |
|---|---|---|---|
|
|
Abingworth Bioventures III LP Venture capital fund |
N/A | |
|
|
Essex Woodlands Health Ventures Inc |
+1 (281) 364-1555 |
N/A |
|
|
ETV Capital SA |
+44 (20) 7907-2370 |
N/A |
|
|
Gilde Investment Management |
Series C | |
|
|
Hercules Technology Growth Capital Inc Specialised finance company providing debt and equity growth capital to technology-related companies at all stages of development. |
+1 (703) 245-3184 |
N/A |
|
|
Phase4 Ventures Ltd |
+44 (20) 3036-0050 |
Series C |
|
|
University of Cambridge |
N/A | |
|
|
Wellcome Trust |
Series C |